Vaccination with Bacillus Calmette–Guérin (BCG) can be harmful to patients with combined primary immunodeficiencies. We report the outcome of BCG vaccination in a series of twelve patients affected by adenosine deaminase deficiency (ADA-SCID). BCG vaccination resulted in a very high incidence of complications due to uncontrolled replication of the mycobacterium. All patients who developed BCG-related disease were treated successfully and remained free from recurrence of disease. We recommend the prompt initiation of enzyme replacement therapy and secondary prophylaxis to reduce the risk of BCG-related complications in ADA-SCID patients.

Outcome of BCG Vaccination in ADA-SCID Patients: A 12-Patient Series / Canarutto, D.; Oltolini, C.; Barzaghi, F.; Calbi, V.; Migliavacca, M.; Tucci, F.; Gallo, V.; Consiglieri, G.; Ferrua, F.; Recupero, S.; Cervi, M. C.; Al-Mousa, H.; Pituch-Noworolska, A.; Tassan Din, C.; Scarpellini, P.; Silvani, P.; Fossati, C.; Casiraghi, M.; Cirillo, D. M.; Castagna, A.; Bernardo, M. E.; Aiuti, A.; Cicalese, M. P.. - In: BIOMEDICINES. - ISSN 2227-9059. - 11:7(2023), p. 1809. [10.3390/biomedicines11071809]

Outcome of BCG Vaccination in ADA-SCID Patients: A 12-Patient Series

Canarutto D.;Consiglieri G.;Ferrua F.;Recupero S.;Castagna A.;Bernardo M. E.;Aiuti A.;Cicalese M. P.
2023-01-01

Abstract

Vaccination with Bacillus Calmette–Guérin (BCG) can be harmful to patients with combined primary immunodeficiencies. We report the outcome of BCG vaccination in a series of twelve patients affected by adenosine deaminase deficiency (ADA-SCID). BCG vaccination resulted in a very high incidence of complications due to uncontrolled replication of the mycobacterium. All patients who developed BCG-related disease were treated successfully and remained free from recurrence of disease. We recommend the prompt initiation of enzyme replacement therapy and secondary prophylaxis to reduce the risk of BCG-related complications in ADA-SCID patients.
2023
enzyme replacement therapy
gene therapy
isoniazid
newborn screening
rifampin
tuberculosis
File in questo prodotto:
File Dimensione Formato  
biomedicines-11-01809-v3.pdf

accesso aperto

Tipologia: PDF editoriale (versione pubblicata dall'editore)
Licenza: Creative commons
Dimensione 847.14 kB
Formato Adobe PDF
847.14 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/198759
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact